AGFG1

Across TCGA pan-cancer cohorts, AGFG1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of AGFG1’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where AGFG1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types AGFG1 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

COAD, HNSC, and LUAD are the cancer types where AGFG1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AGFG1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	II,III,IV	+0.284	<.001	11	view →
HNSC	Male	II,III,IV	+0.234	<.001	8	view →
LUAD	All	All	−0.101	<.001	7	view →
PDAC	Female	II,III,IV	+0.379	<.001	5	view →
LSCC	Male	All	−0.122	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

AGFG1–COAD

Open the COAD breakdown →